Hankin Group’s Post

Exciting news for Velocity! Send me a direct message for additional information on how this platform transforms businesses' internal order processes & operations!

Hankin Group recently welcomed Excision Medical, Inc. to Eagleview, joining Exton's thriving life sciences hub. Excision Medical is a privately held medical device company focused on structural heart technology innovations. Read more about the move in VISTA.Today: https://lnkd.in/ec-7_y-5 #RealEstateNews #LifeSciences

A recent analysis of 2023/2024 profit margins for major medical device companies put Mindray at the top, achieving a remarkable 37.4% net profit margin—outperforming industry giants worldwide. So, what’s their winning formula? 1) competitive pricing, 2) sharp operational efficiency, 3) deep R&D investments, 4) robust cash flow. With this formula, Mindray has consistently pushed gross margins beyond 65% and net margins over 30%. In a $616B global med-tech market, this isn’t just about profit—it’s a blueprint for long-term impact. High profitability doesn’t just drive shareholder value; it powers groundbreaking R&D, attracts top talent, and fuels the highest standards in product quality. - Can other med-tech players keep up in this high-stakes race? - As demand continues to surge, are we about to witness a new era of fierce competition and innovation in med-tech? #MedTech #Mindray #Profitability #Efficiency #Innovation

At Meddux, we're committed to spearheading advancements in the medical device industry through our commitment to the CDMO model. Grounded in pillars of trust, expertise, and operational efficiency, we serve as your dedicated partners as you navigate the complexities of medical innovation. Our methodology is deeply rooted in user-centered design, ensuring that each product we engineer is finely tuned to your end-users’ unique needs to facilitate market adoption. Moreover, our comprehensive suite of services covers every stage of the product development process, from concept generation and ideation to the rigorous demands of commercial manufacturing. Our modular-based approach seamlessly integrates into your existing processes, enhancing efficiency and driving innovation across the board. Choosing Meddux isn't just a decision; it's a strategic investment in the success of your medical innovation. Ready to lead the charge in MedTech innovation? Partner with us to accelerate your product's journey and drive industry change. Learn more at https://lnkd.in/gV7gikkz #Meddux #CDMO #MedicalInnovation #UserCenteredDesign #ProductDevelopment #HealthTech #InnovationLeadership

Arlington Capital acquires TEAM Technologies to bolster healthcare portfolio Arlington Capital has signed a deal to acquire US-based medical device firm TEAM Technologies from Clearlake Capital for an undisclosed sum. The post Arlington Capital acquires TEAM Technologies to bolster healthcare portfolio appeared first on Medi... https://lnkd.in/e8hK2rAB #BioTech #science

We’re excited to welcome COFORCE Medical to the Catcher family!   Previously part of GIMER Medical, 張季衡 Rex Chang, Wei-Ming Chen and their team bring with them deep experience in implantable neuromodulation R&D as well as CDMO capabilities, that provide comprehensive, customized, and integrated solutions. This marks a significant milestone in our relentless journey to become a leader in the medtech CDMO space while simultaneously maintaining a culture of innovation and excellence.   By integrating cross-disciplinary platforms that complement Catcher’s core strengths in material science and precision manufacturing, we strive to deliver ever greater value for our medtech partners and customers globally.   #CatcherMedical #PartnershipsforLife

Pioneering a New Medical Device? The Path is Arduous, but Meddux Makes It Achievable! Introducing an innovative medical device to the world involves a journey rife with hurdles. From brilliant concept to life-changing commercialization, the path demands relentless problem-solving. At Meddux, we embrace the challenges in this adventure, serving as the experienced guide to lead you through uncharted territory. Our passion? Transforming visions into real-world solutions that improve lives. First-In-Human Studies Conducting clinical trials requires flawless execution. We provide the critical capabilities: ✅ Rapid delivery of initial product builds ✅ Rigorous quality systems for clinical-grade devices ✅ Proven expertise in managing risk and compliance Commercial Launch Whether initiating a controlled pilot or scaling to full commercialization, our flexibility powers your success: 📈 Limited pilot builds to validate market entry 💪 Scalable manufacturing for commercial volumes 🔄 Continuous process improvement for cost optimization With decades of experience, we've forged a trail for countless companies navigating from concept to market delivery. Our passion and process empower you to defy limitations. Read how we guided an electrosurgical device pioneer: https://lnkd.in/gBuakSj5

You're a pre-commercial start-up and Johnson & Johnson announces a blockbuster acquisition in your space. What do you do? How does this affect you? Does this validate the market or make it more difficult? Do you have to change your commercialization strategy? Do you have to accelerate? We dig into one of the biggest stories in medical devices this year with Sean Gilligan and Robert Chisena. - Watch the full episode here: https://hubs.ly/Q02Q6qDd0 - Amplitude Vascular Systems MassMEDIC Boyd Biomedical

Trinity's Deepak Sahu, Managing Director, was featured in Citeline's article, "Medtech 2025: What Difference Does a Year Make?" Read his thoughts below.    "2024 was the year of a return to larger transactions, including Johnson & Johnson’s $13.1bn acquisition of Shockwave Medical and Boston Scientific’s $3.7bn purchase of Axonics.   2025 will be the year of more cross-border deals with increased focus on expanding into APAC and MEA regions. Hospital systems will further adopt payment-per-procedure business models for innovative yet capital-intensive technologies. While these models may increase procurement prices over the device’s lifetime, they will provide hospitals with better cost control, addressing ongoing cash flow constraints."   For the full article visit: https://lnkd.in/g2AZRWix

Big news in Medtech! Merit Medical just made a bold $105M move, scooping up the EsophyX Z+ device from EndoGastric Solutions. This isn't just a win for Merit; it's a game-changer for those battling GERD. This smart addition is all about minimally invasive treatment, offering fresh hope and cutting-edge care without a single incision. With Merit Medical's focus on strategic growth, this deal isn't merely a purchase; it's a leap forward expanding their reach in gastrointestinal care. Thoughts on how this acquisition might change the playing field? Drop your take below! #Medtech #Innovation #HealthcareIndustry